Investor Presentaiton slide image

Investor Presentaiton

SP0125 demonstrated safety profile similar to placebo sanofi First administration Participants experiencing at least one unsolicited AE within 28 days after vaccination RSVt LD (n=61) RSVt HD (n=57) Placebo (n=61) RSVt LD (n=48) Second administration RSVt HD (n=48) Placebo (n=54) n (%) n (%) Not related to vaccination 37 (60.7) 30 (52.6) n (%) 38 (62.3) n (%) 22 (45.8) n (%) 17 (35.4) Related to vaccination 5 (8.2) 6 (10.5) 4 (6.6) 4 (8.3) 3 (6.3) n (%) 23 (42.6) 2 (3.7) AE of special interest* 15 (24.6) 8 (14.0) 15 (24.6) 7 (14.6) 5 (10.4) 6 (11.1) Medically attended AE 28 (45.9) 23 (40.4) 26 (42.6) 19 (39.6) 14 (29.2) 17 (31.5) AE leading to study discontinuation 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Serious AE Death 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) * Based on investigator assessment. AE of special interest: acute otitis media, upper and lower respiratory infections. 33 Vaccines Investor Event
View entire presentation